Breaking Down Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Financial Health: Key Insights for Investors

A closer look at Yantai Dongcheng Pharmaceutical Group (002675.SZ) reveals a company at a crossroads: reported revenue fell to CNY 2.87 billion in FY2024 (down 12.42% from CNY 3.28 billion) and TTM revenue as of 30‑Sep‑2025 sits at CNY 2.75 billion (‑3.62% YoY), driven largely by an 18.80% plunge in the API segment (CNY 1.39 billion) even as Nuclear Medicine grew 3.94% to CNY 1.06 billion; profitability shows a net income of CNY 183.8 million in 2024 (net margin ~6.4%) and TTM EPS of CNY 0.20 (P/E ~69.29) while liquidity metrics include CNY 943.41 million in cash against total debt of CNY 851.87 million and a conservative debt/equity of 0.16; valuation and market expectations are rich (market cap CNY 12.37 billion, trailing P/E 77.00, EV/EBITDA 30.21) even as analysts forecast earnings growth of 30.5% p.a. and revenue growth of 12.7% p.a.-read on for a chapter‑by‑chapter breakdown of revenue drivers, margins, balance‑sheet health, valuation risks, and the growth levers behind Yantai Dongcheng's next moves.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Revenue Analysis

• Primary drivers of the 2024 decline: an 18.80% drop in the Active Pharmaceutical Ingredient (API) segment.
• Offsetting growth: Nuclear Medicine rose 3.94% in 2024, contributing CNY 1.06 billion.
• Scale metrics: workforce of 2,469 employees; revenue per employee ≈ CNY 1.11 million.
• Geographic reach: products sold to more than 40 countries and regions, supporting international diversification.

• Segment mix in 2024: API ~48.4% of revenue (CNY 1.39B of CNY 2.87B), Nuclear Medicine ~36.9% (CNY 1.06B).
• Implication: API weakness is the principal near-term headwind; Nuclear Medicine provides resilience and modest growth.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Profitability Metrics

Key profitability indicators for Yantai Dongcheng Pharmaceutical Group Co.,Ltd. provide a snapshot of earnings efficiency, cost structure and returns to shareholders. Below are the primary metrics and contextual figures investors often track.

• Net income (2024): CNY 183.8 million - net profit margin ~6.4%.
• Trailing twelve months EPS (as of 2025-09-30): CNY 0.20; P/E ratio: 69.29.
• Return on equity (ROE): 1.68% - modest return relative to shareholders' equity.
• Operating margin (TTM): 15.66% - reflects operating expense management.
• Gross margin: 47.81% - portion of revenue after cost of goods sold.
• EBITDA margin: 14.93% - operating earnings before D&A, interest and taxes as a share of revenue.

• High gross margin (47.81%) indicates strong product-level pricing or low COGS relative to revenues.
• Operating and EBITDA margins (~15-15.7%) suggest reasonable operational efficiency before non-operating items.
• Lower net margin (6.4%) and ROE (1.68%) point to material non-operating costs, taxes, interest, or equity base dilution affecting returns.
• Elevated P/E (69.29) versus EPS (CNY 0.20) implies market expectations for future growth or reflects low current earnings.

For broader company context and background, see: Yantai Dongcheng Pharmaceutical Group Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Debt vs. Equity Structure

Yantai Dongcheng Pharmaceutical Group's balance between liabilities and equity through the quarter ended June 30, 2025 shows a conservative leverage profile paired with moderate coverage metrics and a relatively high valuation versus cash- and earnings-based measures.

• Total debt stands at CNY 851.87 million while total cash is CNY 943.41 million, producing a net cash position on a simple cash vs. debt basis.
• Debt-to-equity ratio of 0.16 indicates limited reliance on debt financing relative to shareholders' equity.
• Current ratio of 1.65 and quick ratio of 1.21 signal sufficient short-term liquidity to meet obligations, with immediate asset coverage above 1.0.
• Interest coverage ratio of 2.38 implies operating income covers interest expense about 2.4 times - adequate but not ample cushion against operating volatility.
• High valuation multiples - EV/EBITDA at 30.21 and EV/FCF at 65.27 - point to a market pricing that demands strong future growth or margin stability to justify value.

Key implications for investors:

• Low leverage reduces balance-sheet default risk and provides flexibility for opportunistic investments or buffering against downturns.
• Positive net cash (cash > debt) supports short-term obligations and potential capital allocation choices (capex, dividends, buybacks), though actual policy should be checked in disclosures.
• Interest coverage above 2x is acceptable but vulnerable to margin compression; sustaining operating income is important to maintain comfort.
• Very high EV multiples suggest the market expects above-average growth or persistent high margins; investors should reconcile multiples with revenue growth, margin trends, and pipeline/product mix.
• Liquidity ratios above 1 provide reassurance for near-term obligations, but quick ratio closer to 1.2 shows less buffer if receivables/inventory deteriorate.

For historical context, governance and business model details relevant to interpreting these metrics, see: Yantai Dongcheng Pharmaceutical Group Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Liquidity and Solvency

• Total cash position: CNY 943.41 million - a clear short-term buffer for working capital and interest obligations.
• Trailing twelve months operating cash flow: CNY 572.54 million - demonstrates solid cash generation from core operations.
• Free cash flow: CNY 62.2 million - positive but comparatively modest after capital expenditure.
• Debt-to-EBITDA ratio: 1.94 - indicates leverage of just under two times EBITDA, a moderate level for a pharmaceutical manufacturer.
• Debt-to-free cash flow ratio: 4.20 - highlights higher leverage when measured against free cash available to service debt.
• Interest coverage ratio: 2.38 - operating income covers interest expense by ~2.4x, a comfortable but not wide margin.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Valuation Analysis

• Market Capitalization: CNY 12.37 billion
• Enterprise Value (EV): CNY 13.25 billion
• Trailing P/E: 77.00
• Forward P/E: 42.10
• Price-to-Sales (P/S): 4.37
• Price-to-Book (P/B): 2.27
• Price-to-Tangible Book Value (P/TBV): 7.28
• Price-to-Free Cash Flow (P/FCF): 60.95

• High trailing and forward P/E differentials: implies investors price in material earnings growth; verify management guidance and pipeline catalysts.
• Elevated P/TBV and P/B: check intangible asset composition, goodwill, R&D capitalization, and asset impairment history.
• High P/FCF: review recent cash flow trends, capex plans, and working capital cycles to assess cash conversion risk.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Risk Factors

• Core API revenue contraction: The API segment recorded an 18.80% decline in revenue in 2024, a material weakening in the company's traditional earnings engine that can compress margins and reduce scale advantages.
• Capex vs. cash generation: Capital expenditure reached CNY 456 million in 2024 and exceeded operating cash flow, producing negative free cash flow and raising questions about the sustainability and timing of returns on these investments.
• Leverage profile nuances: The debt-to-equity ratio is a conservative 0.16, signaling limited reliance on debt financing, but the debt-to-EBITDA ratio of 1.94 indicates moderate leverage relative to earnings and potential sensitivity if EBITDA declines.
• Valuation risk: A trailing P/E of 77.00 implies elevated market expectations; any earnings shortfall or continued top-line weakness could prompt significant multiple compression.
• Low market volatility: Beta of 0.065 suggests the stock has moved very little relative to the broader market - attractive to risk-averse investors but potentially indicative of limited upside participation in bullish cycles.
• Profitability pressure: Net profit margin at 6.4% is modest for the sector and may offer limited buffer against rising costs, pricing pressures, or further revenue declines.

• Near-term implications for investors:
  • Revenue recovery is crucial - continued API declines may force margin remediation, cost cutting, or strategic asset reallocation.
  • Negative FCF amid heavy capex suggests scrutiny of project returns and potential need for external funding if operating cash generation does not improve.
  • High P/E elevates execution risk: management must deliver growth and margin expansion to justify current valuation.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Growth Opportunities

• Analysts' forward-looking estimates: earnings CAGR of 30.5% and revenue CAGR of 12.7%, signaling a strong growth runway.
• Low market volatility: beta of 0.065, attractive for investors seeking steadier exposure to pharmaceutical growth.

Core expansion drivers and strategic levers that underpin these forecasts:

• Formulation pipeline breadth:
  • Therapeutic coverage includes anticoagulation, oncology, and anti-infectives - enabling multiple market entry points and lifecycle management opportunities.
• Nuclear medicine / nuclide drug entry:
  • Established a leading position in China's nuclear medicine field, positioning the company in a high-growth, specialty segment with premium pricing and limited competition.
• International footprint:
  • Products sold to over 40 countries, providing diversification of revenue streams and scalable export growth potential.
• R&D commitment:
  • Significant investment in scientific research supports innovation-driven product launches and pipeline advancement.

• Investor implications:
  • High earnings CAGR vs. moderate revenue CAGR suggests margin expansion or higher-margin product mix (e.g., nuclear medicine, specialty formulations).
  • Global distribution and diversified therapeutic pipeline reduce single-market and single-product concentration risk.
  • Low beta may appeal to risk-averse investors seeking exposure to pharmaceutical innovation with comparatively muted share-price volatility.